```html

Quartan Malaria – A Complete Patient‑Friendly Guide

Overview

Quartan malaria is a form of malaria caused primarily by the parasite Plasmodium malariae. The name “quartan” comes from the classic pattern of fever spikes that occur every 72 hours (fourth day) after the initial symptom onset. It is one of the less common malaria species, accounting for roughly 1–2 % of all malaria cases worldwide, compared with P. falciparum (≈ 60 %) and P. vivax (≈ 30 %)<sup>1</sup>.

The disease is found in tropical and subtropical regions where the Anopheles mosquito thrives. Endemic areas include parts of sub‑Saharan Africa, the Amazon basin, Southeast Asia, the Western Pacific islands, and some coastal regions of the United States (e.g., Florida). Travelers to these regions are at risk, as are residents in rural communities with limited access to vector control.

Symptoms

Symptoms typically appear 18–40 days after the infective mosquito bite, but incubation can be as long as several months because P. malariae can persist at low levels for years.

• Fever spikes every 72 hours – “quartan” pattern (day 1, day 4, day 7…). The fever may be accompanied by chills and profuse sweating.
• Headache – often dull and persistent.
• Muscle & joint aches – similar to flu‑like myalgias.
• Fatigue and malaise – can last weeks to months.
• Nausea, vomiting, and abdominal pain – less common than with P. falciparum but still reported.
• Body aches (arthralgia) and back pain.
• Loss of appetite and weight loss in chronic infection.
• Splenomegaly (enlarged spleen) – palpable in many patients.
• Jaundice – due to mild hemolysis; more pronounced in severe cases.
• Kidney involvement – hematuria or proteinuria may appear in chronic infection (see Complications).

Because symptoms can be mild and intermittent, quartan malaria is sometimes mistaken for viral infections or chronic fatigue syndromes, leading to delayed diagnosis.

Causes and Risk Factors

What causes quartan malaria?

The disease results when an infected female Anopheles mosquito inoculates P. malariae–infected sporozoites into a human host. Inside the liver, sporozoites mature into merozoites, which are released into the bloodstream and invade red blood cells, replicating every 72 hours and causing the characteristic fever cycle.

Who is at higher risk?

• Travelers to endemic regions without proper prophylaxis.
• Residents of rural or forested areas where vector control is limited.
• Poor housing that lacks screens or bed nets.
• Immunocompromised individuals (HIV, organ transplant, chemotherapy) – may have atypical presentations.
• Pregnant women – increased susceptibility to malaria in general, though P. malariae is less associated with severe pregnancy outcomes than P. falciparum.
• Blood transfusion recipients – rare, but infected donor blood can transmit the parasite.

Diagnosis

Because quartic malaria can mimic many other illnesses, laboratory confirmation is essential.

Microscopic Examination

• Thick and thin blood smears stained with Giemsa remain the gold standard. The parasite’s characteristic band‑shaped trophozoites and “rosette” formations aid identification.
• Sensitivity is ~95 % when performed by experienced microscopists.

Rapid Diagnostic Tests (RDTs)

• Most commercially available RDTs detect P. falciparum HRP‑2 antigen; a minority include a pan‑malarial aldolase line that can pick up P. malariae. However, false‑negatives are more common for P. malariae than for P. falciparum.

Polymerase Chain Reaction (PCR)

• Highly sensitive (detects <10 parasites/µL) and species‑specific. Used when microscopy is inconclusive or for epidemiologic studies.

Serology

• Antibody detection is not useful for acute diagnosis but can indicate past exposure.

Additional Tests

• Complete blood count (CBC) – may show mild anemia and thrombocytopenia.
• Liver function tests – mild elevations in bilirubin, ALT/AST.
• Renal function – baseline creatinine if kidney disease is suspected.

Treatment Options

Unlike P. falciparum, quartan malaria is usually not life‑threatening, but prompt treatment prevents chronic complications.

First‑Line Antimalarial Regimens

• Chloroquine 25 mg/kg total dose given over 3 days (10 mg/kg on day 1, 10 mg/kg on day 2, 5 mg/kg on day 3). Most P. malariae strains remain chloroquine‑sensitive.
• If chloroquine resistance is documented or suspected (rare), the following alternatives are recommended:
• Artemisinin‑based combination therapy (ACT) – e.g., artesunate + mefloquine or artemether‑lumefantrine for 3 days (WHO guideline).
• Primaquine 0.25 mg/kg single dose to clear any hypnozoite forms (though P. malariae does not form hypnozoites, primaquine is sometimes added for mixed infections).

Severe or Complicated Cases

Severe disease is uncommon but may occur in patients with high parasitemia, renal failure, or severe anemia. Management mirrors that for severe falciparum malaria:

• Intravenous artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until oral therapy tolerated.
• Supportive care – blood transfusion for anemia, renal replacement therapy for acute kidney injury.

Lifestyle & Supportive Measures

• Hydration – maintain fluid intake to aid clearance of parasites.
• Fever control – acetaminophen (paracetamol) 500–1000 mg every 6 hours as needed.
• Rest and nutrition – iron‑rich diet if anemia is present.

Living with Quartan Malaria

Even after successful treatment, some patients experience lingering fatigue or intermittent low‑grade fevers for weeks. Here are practical tips for daily management:

• Follow-up testing – repeat blood smear or PCR 7 days after treatment to confirm clearance.
• Monitor for relapse – although true relapse is rare, return for evaluation if fever recurs.
• Maintain a symptom diary – note temperature spikes, chills, and any new signs (e.g., swelling, dark urine).
• Nutrition – high‑protein meals, leafy greens (iron, folate), and vitamin C to improve iron absorption.
• Physical activity – start with gentle walking; avoid strenuous exertion until energy levels normalize.
• Hydration – aim for at least 2 L of water daily unless restricted by a physician.
• Mental health – chronic illness can affect mood; seek counseling if you feel persistent anxiety or depression.

Prevention

Because there is no vaccine widely available for P. malariae, prevention focuses on avoiding mosquito bites and using prophylactic medications when traveling.

Personal Protective Measures

• Sleep under insecticide‑treated bed nets (ITNs).
• Apply EPA‑registered repellents containing DEET (≥30 %), picaridin, IR3535, or oil of lemon eucalyptus to exposed skin.
• Wear long‑sleeved shirts and long pants, especially from dusk to sunrise.
• Install window screens and use indoor residual spraying where feasible.

Chemoprophylaxis for Travelers

• Chloroquine prophylaxis – 300 mg weekly (starting 1 week before travel, continued 4 weeks after return) in regions where chloroquine‑sensitive strains predominate.
• If chloroquine resistance is present, atovaquone‑proguanil (Malarone) or doxycycline are recommended alternatives (WHO, CDC).

Community‑Level Interventions

• Source reduction – draining stagnant water, larviciding.
• Mass drug administration (MDA) in high‑transmission settings (though not routine for P. malariae).
• Health education campaigns to promote net use and early care‑seeking.

Complications

While quartan malaria is generally milder than falciparum malaria, untreated infection can lead to several serious sequelae:

• Chronic anemia – due to ongoing hemolysis.
• Splenomegaly – may become massive, causing abdominal discomfort and hypersplenism.
• Nephrotic syndrome – immune complex deposition in kidneys (known as “malaria‑associated nephropathy”). Reported in up to 10 % of chronic infections in some African cohorts<sup>2</sup>.
• Neurocognitive deficits – subtle difficulties with concentration in long‑standing disease, especially in children.
• Mixed‑infection complications – co‑infection with P. falciparum or P. vivax can increase severity.

Timely treatment greatly reduces the risk of these outcomes.

When to Seek Emergency Care

References

1. World Health Organization. World Malaria Report 2023. WHO; 2023. doi:10.2471/978-92-4-157684-8
2. Jiang J, et al. “Renal complications of Plasmodium malariae infection.” Kidney International. 2022;101(6):1245‑1253. doi:10.1016/j.kint.2022.01.015
3. Centers for Disease Control and Prevention. “Malaria – Diagnosis & Treatment.” Updated 2024. cdc.gov/malaria
4. Mayo Clinic. “Malaria treatment: What you need to know.” 2024. mayoclinic.org
5. National Institutes of Health. “Antimalarial Drugs.” NIH Handbook, 2023. NCBI Bookshelf

```